RayKnowChina Research Map
Shortlist

Zhengzhou

First Affiliated Hospital of Henan University of Chinese Medicine

河南中医药大学第一附属医院

Listed for 3 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Henan University of Chinese Medicine

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  2. Idiopathic pulmonary fibrosis特发性肺纤维化14 papers led
  3. IgA nephropathyIgA 肾病3 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Zhengzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. Anti-N-methyl-D-aspartate receptor encephalitis: a prospective study focused on cerebrospinal fluid and clinical symptoms.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 14 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.4%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 4420232024: 3320242025: 332025

8 hospitals in Zhengzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Daoyin Technique for Improving Exercise Endurance in IPF
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07019714

    Age 40 years to 85 years (registered criteria)

    Led by Affiliated Hospital of Liaoning University of Traditional Chinese Medicine; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou

  2. Recruiting
    Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT06914713

    Age 40 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led14
  1. Health-related quality of life and health state utility value in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.2025Health and quality of life outcomes
  2. Mechanistic insights into the treatment of pulmonary fibrosis with bioactive components from traditional chinese medicine via matrix stiffness-mediated EMT.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Clinical efficacy and safety of anticoagulants in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.2025Therapeutic advances in respiratory disease
  4. Identification of idiopathic pulmonary fibrosis hub genes and exploration of the mechanisms of action of Jinshui Huanxian formula.2024International immunopharmacology
  5. Patient-Reported Outcome Scale for Idiopathic Pulmonary Fibrosis: Development and Validation in China.2024Journal of evidence-based medicine
  6. The incidence of acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.2024Scientific reports
  7. Integrated bioinformatics analysis for the identification of idiopathic pulmonary fibrosis-related genes and potential therapeutic drugs.2023BMC pulmonary medicine
  8. Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial.2023Journal of integrative medicineRCT
  9. Effective-compounds of Jinshui Huanxian formula ameliorates fibroblast activation in pulmonary fibrosis by inhibiting the activation of mTOR signaling.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  10. The role of pulmonary rehabilitation in idiopathic pulmonary fibrosis: An overview of systematic reviews.2023PloS one
  11. PTEN: An Emerging Potential Target for Therapeutic Intervention in Respiratory Diseases.2022Oxidative medicine and cellular longevity
  12. Identification of the active compounds and functional mechanisms of Jinshui Huanxian formula in pulmonary fibrosis by integrating serum pharmacochemistry with network pharmacology.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  13. Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.2022Trials
  14. Efficacy and safety of traditional Chinese medicine in patients with acute exacerbation of idiopathic pulmonary fibrosis: study protocol for randomized, controlled, exploratory clinical trial.2022Trials
Chinese-language papers (not in the count)1
  1. [Evidence mapping of clinical research on traditional Chinese medicine in treatment of idiopathic pulmonary fibrosis].2024Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
Earlier papers (2016–2020)4
  1. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial.2020Journal of integrative medicine
  2. Pulmonary Rehabilitation for Exercise Tolerance and Quality of Life in IPF Patients: A Systematic Review and Meta-Analysis.2019BioMed research international
  3. [Umbilical moxibustion for patients with idiopathic pulmonary fibrosis complicated with gastroesophageal reflux of lung-spleen qi deficiency].2019Zhongguo zhen jiu = Chinese acupuncture & moxibustionRCT
  4. Acupuncture for idiopathic pulmonary fibrosis: Protocol for a systematic review.2017Medicine
All its trials on ClinicalTrials.gov, any status5
  1. Daoyin Technique for Improving Exercise Endurance in IPFRecruitingNCT07019714Study siteN/AStart 2026-04
  2. Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPFRecruitingNCT06914713Study siteN/AStart 2025-09
  3. Idiopathic Pulmonary Fibrosis Cohort of TCMNot yet recruitingNCT07162870Study siteStart 2025-09
  4. Disease-syndrome Characteristics of IPFNot yet recruitingNCT07178392Study siteStart 2025-09
  5. Jin-shui Huan-xian Granule in the Treatment of IPFStatus unknownNCT04187690Study siteN/AStart 2020-09

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

3 hospitals in Zhengzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

河南中医药大学第一附属医院

First Affiliated Hospital of Henan University of Chinese Medicine

郑州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data